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Graphical Abstract 
Better than nature: facile synthesis of 
tryptophan derivatives 
G. Blaser, J. M. Sanderson, A. Batsanov, J. A. K. Howard  
Department of Chemistry, DurhamUniversity,  
South Road, DH1 3LE, Durham, UK 
 
Tryptophan derivatives can be easily  
synthesised at room temperature 
using a a wide range of indole 
derivatives. 
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  Better than nature: facile synthesis of tryptophan derivatives 
Georg Blaser,a John M. Sanderson,a,* Andrei Batsanova and Judith A. K. Howarda  
aDurham University, Department of Chemistry, South Road, Durham DH1 3LE, UK 
 
Abstract—Tryptophan is an essential amino acid important as protein building block, for the anchoring and binding of membrane proteins, 
substrate in biosynthetic reactions, and as versatile label in protein folding and location studies. As fluorescent molecules, tryptophan 
derivatives are especially useful in the exact determination of 3-dimensional protein structure in solution and in bound states. This study 
reports a facile method to synthesise a variety of tryptophan derivatives that are difficult to prepare using alternative enzymatic approaches. 
© 2011 Elsevier Science. All rights reserved. 
——— 
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Introduction 
Tryptophan is a ubiquitous essential amino acid. A building 
block of nonribosomal peptides and alkaloids, it has been 
recognised that tryptophan plays an important role in the 
binding and anchoring of membrane proteins to the lipid 
bilayer of cells.i Furthermore, molecular tryptophan is also 
a substrate for the biosynthesis of molecules such as the 
antifungal, pyrrolnitrin, which proceeds via the cleavage of 
7-chlorotryptophan.ii Due to their fluorescent properties, 
tryptophan derivatives, are commonly used as probes to 
determine the 3 dimensional structures and intra- as well as 
inter molecular distances within proteins and protein 
complexes.iii,iv  
Derivatisation of natural products as simple as mono-
substitutions and the commonly found introduction of 
halogen atoms can dramatically impact on the compounds 
bioactivity and bioavailability.v Halogenated amino acids 
are also activated as possible substrates for further selective 
functionalisation through reactions such as the Suzuki and 
the Sonogashira coupling. 
 
 
Figure 1: Tryptophan .structures synthesised, where R1 = H, F, Cl, Br, I, 
MeO, NO2; R2 = H, F, Cl, Br, Me, MeO, NO2 
Tryptophan can be synthesised using a variety of chemical 
and enzymatic methods; amongst the latter, tryptophan 
synthase has received much attention.vi This enzyme uses 
indole-3-glycerol phosphate and L-serine as substrates to 
produce L-tryptophan in two sequential reactions. Although 
a variety of substrates is accepted, the accessibility of the 
enzyme active site places restrictions on the production of a 
wide range of tryptophan derivatives. Mono-substituted 
indoles on position 4 and 7 on the indole ring (Figure 1) are 
normally poor  substrates.vi A range of substitutions on the 
ring positions 5 and 6 is tolerated but bulky groups like 
 
Pergamon 
TETRAHEDRON 
LETTERS 
5
6
7
7a
3a
4
N
H
1
2
3
R2
NH2R1
CO2H
 Tetrahedron Letters  2 
iodo or nitro-substituents or extended alkyl groups cannot 
be accommodated by the enzyme. 
 
 
 
 
Table 1. 5-Indole reaction with L-serine 
No. Indole Derivative Ac2O (equiv) Yield (%) 
1 R1 = F 2.0 82 
2 R1 = Cl 2.0 86 
3 R1 = Br 2.0 77 
4 R1 = I 1.5 74 
5 R1 = MeO 1.0 80 
6 R1 = NO2 2.5 44a 
a Lower yield due to electron withdrawing nitro group. 
Chemical synthesis can be achieved by a classical SN2 
nucleophilic attack of the C3 indole carbon on an activated 
electrophile, followed by E1 elimination to restore 
aromaticity of the ring. The nucleophilic attack is site-
specific and stabilised through resonance. If serine is used 
as electrophile, under the appropriate conditions the 
resulting product will be a simple tryptophan analogue. 
Using the right stoichiometry, near quantitative reaction 
can be achieved, while excess electrophile will be directed 
onto the C2 position. Using such a chemical approach has 
the advantage that there are virtually no restrictions in 
terms of the indole derivates that may be used, giving 
access to a wide range of products. In this article, we 
describe the synthesis of a range of 5- and 6-substituted 
tryptophan derivatives by electrophilic substitution and 
their subsequent resolution using enzymatic methods. 
Results 
Using a chemical approach, a wide range of tryptophan 
derivatives was produced. The products cover a broad 
spectrum of electron density on the indole ring 
demonstrating the feasibility of the reaction for a range of 
indole derivatives. Reaction yields of up to 98% were 
achieved for the initial preparation of Να-acetylated 
tryptophan derivatives (Tables 1 and 2). The enzymatic 
separation of enantiomers made both the free L-amino acid 
and the corresponding Nα-acetyl D-enantiomer readily 
available. The L-tryptophan derivative could be used 
directly for further derivatisation such as the introduction of 
an Fmoc protecting group rendering it as a good substrate 
for standard solid phase peptide chemistry.  
The D-enantiomer can be both used to study the naturally 
less abundant enantiomer of the amino acid or racemised 
and recycled to produce more L-enantiomer.  
Table 2. 6-Indole reaction with L-serine 
No. Indole Derivative Ac2O (equiv) Yield (%) 
7 R2 = F 2.0 98 
8 R2 = Cl 2.0 86 
9 R2 = Br 2.0 73 
10 R2 = Me 1.5 73 
11 R2 = MeO 1.0 77 
12 R2 = NO2 2.5 58a 
a Lower yield due to electron withdrawing nitro group. 
Discussion 
The feasibility and applicability of the synthesis method 
depends on the electron density distribution on the indole 
ring. Electron rich indole derivatives such as 5 and 11 were 
found to be highly reactive towards electrophilic attack. 
The less electron rich indoles 6 and 12 were less reactive 
and an excess of the electrophile had to be used to achieve 
moderate yields. The most likely side-reaction was found to 
be a double-attachment of the electrophile on position C2 
and C3 on the indole ring. These are the classical sites for 
reactions on the indole ring as the partial electron density is 
highest on these carbon centres. The side-reaction could be 
minimized by adjusting the stoichiometry accordingly by 
increasing the amount of electrophiles slightly for electron 
deficient indole compounds and reducing the amount of 
electrophiles for electron rich indole derivatives. Multiple 
substitution might also be achieved by dilution of the 
sample. 
In contrast to this chemical approach, enzymatic 
approaches to the synthesis of tryptophan derivatives are 
limited by the substrate restrictions posed by the enzyme. 
In tryptophan synthase, indole must first enter the α subunit 
and pass through a 2.5 nm long tunnel before it reaches the 
active site in the β subunit.vii Indoles with substitutions on 
the 4 or 7 position will have the greatest width and 
therefore, may be blocked or hindered. The reported yields 
for such substrates were poor.vi Other sterically hindered 
substrates such as iodo- or nitro-substituted compounds 
may not be converted at all. 
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The yields of the chemical reaction could be improved by 
recycling unreacted indole starting material from the 
organic extraction. 
A drawback of the reaction is racemisation of the amino 
acid stereocentre under the coupling conditions. Working 
under strongly acidic conditions implied that the observed 
racemization neither proceeded via oxazolone formation, 
nor via a classical direct enolization of the serine, both of 
which require the presence of a base. The mechanism by 
which the reaction might proceed has been discussed: it 
was proposed that in the enzymatic pathway of tryptophan 
synthase, the reactive L-serine intermediate is an 
aminoacrylate.viii A patent was filed claiming a reaction 
between indole derivatives and N-acetylated aminoacrylic 
acid in 1954.ix However, there is another paper suggesting a 
different route.ref 
 
 
 
Figure 2: 2-acetamido acrylic acid crystal structure. 
2-Acetamido acrylic acid (Figure 2) was identified as a by-
product of the reaction in our case, being isolated from 
reactions with less reactive indoles such as 5- and 6-
nitroindole. This suggested that it was an intermediate in 
the reaction, consistent with the loss of the stereocentre. It 
was believed to have formed via an elimination reaction of 
serine through loss of AcOH from the acylated 
intermadiate. However, when L-serine was reacted with an 
excess of acetic anhydride (5 equiv.) in glacial acetic acid, 
the major product was found to be doubly acetylated D,L-
serine. No presence of 2-acetamido acrylic was detected in 
this control experiment in the absence of an indole 
derivative. This indicates that the acrylic acid is likely to be 
an unstable reaction product, which, under the reaction 
conditions with acetic anhydride in vast excess, reacted to 
form the more stable Nα-acetyl-Oβ-acetyl serine (Ac-
Ser(Ac)-OH). 
Experimental 
Chemicals and Reagents. Chemicals and reagents of the 
were obtained from Sigma Aldrich or Fisher Scientific UK 
if not stated otherwise. All reagents were of the highest 
quality and were used without further purification. 
Deuterated solvents were used as supplied from GOSS. The 
enzyme “Amano Acylase” was used as purchased from 
Amano Enzyme Inc., Nagoya, Japan.  
Synthesis 5- & 6-mono-substituted tryptophan derivatives. 
L-serine (0.2 mmol) was dissolved in a solution of the 
substituted indole (0.1 mmol) in acetic acid (0.24 ml) and 
acetic anhydride (0.9 mmol). The mixture was stirred under 
argon at 73 °C for 2 h. Upon cooling the solution was 
treated with diethyl ether (2 ml), adjusted to pH 11 using 
30% sodium hydroxide solution and further diluted with 
ether (3 ml). The layers were partitioned and treated 
separately. The ether layer was further extracted with 1 N 
sodium hydroxide solution (2 x 2 ml) and a small amount 
of sodium thiosulphate Na2S2O4 was added. The aqueous 
solutions were combined, neutralized to pH 7 using 
concentrated hydrochloric acid and the volume reduced to 
50% by evaporation under vacuum. If precipitation 
occurred, samples were stored at 4 °C for 24 hours to allow 
further precipitation. Precipitates were filtered and dried 
under vacuum. The filtrate was further concentrated to half 
its original volume and any further precipitates collected. 
Otherwise the filtrates were acidified to pH 3 with 5% 
hydrochloric acid, extracted with ethyl acetate (3 x 7 ml) 
and dried over magnesium sulphate. After filtration, the 
solvent was removed under vacuum and the residue treated 
with benzene and re-evaporated to yield the desired mono-
substituted D,L-tryptophan derivative. The ether layer was 
dried over magnesium sulphate. Removal of the solvent 
under vacuum recovered unreacted indole starting material. 
Enzymatic resolution of 5- & 6-mono-substitued D,L- 
tryptophan derivatives. Borate buffer solution was prepared 
from sodium tetraborate decahydrate (1.9 g, 0.05 M) in 
deionised water (100 ml). The pH was adjusted to pH 8.00 
using concentrated hydrochloric acid. Cobalt(II) chloride 
hexahydrate (0.5 mg, 3.9 µmol) was added to a final 
concentration of 0.125 mM. 
N-acetylated-D,L-tryptophan amino acid (0.40 mmol) was 
dissolved in borate buffer solution (5 ml). A solution of 
acylase (100 mg) in borate buffer (10 ml) was added under 
stirring. The reaction mixture was stirred at 37 °C for 48 
hours. The reaction was quenched by adjusting the pH to 5 
using 10% hydrochloric acid. Subsequently the mixture 
was filtered through a celite pad and the filtrate extracted 
into ethyl acetate (3 x 25 ml). The organic layer was dried 
over magnesium sulphate, filtered and the solvent removed 
under vacuum to afford the crude unreacted N-acetyl-D-
tryptophan derivative. The aqueous phase was purified by 
ion-exchange chromatography using DOWEX® Resin 
50X2-200. The resin was prepared prior to the run through 
deprotonation and protonation via 0.1 M sodium hydroxide 
solution and 0.1 M hydrochloride solution respectively. 
Water and methanol eluents were used to wash the resin 
before its application. The column was prepared for loading 
by protonation of the acceptor sites with 0.1 M HCl 
solution. The product, dissolved in the aqueous phase, was 
then applied to the column and eluted first with water (150 
ml) and then with 10% ammonia in methanol (200 ml). 
Fractions which showed UV activity and responded 
positively to a ninhydrin test were collected and the solvent 
removed under vacuum to afford the L-enantiomer of the 
free amino acid. 
Methyl-Esterification: N-Acetylated-L-tryptophan amino 
acid (0.1 mmol) was dissolved in excess methanol (5 ml). 
Concentrated sulphuric acid (0.15 ml) was added as a 
N
H
O
OH
O
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catalyst. The reaction mixture was refluxed for 2 hours and 
neutralized upon cooling using 0.5 M aqueous sodium 
carbonate solution. The solvents were removed under 
vacuum and the residues re-dissolved in deionised water (2 
ml). The product was extracted from the aqueous phase 
using dichloromethane (3 x 2 ml). The organic layer was 
separated and washed with 0.5 M aqueous sodium 
carbonate solution (2 ml) and deionised water (2 x 2 ml). 
The DCM mixture was then dried over magnesium 
sulphate, filtered and the solvent removed under vacuum to 
yield the crude product which was used without further 
purification for the ethyl amidation reaction. 
Ethyl amidation. The N-acetylated-L-tryptophan methyl 
ester derivative (0.1 mmol) was dissolved in a solution of 
ethylamine in methanol (50 % v/v) (5 ml). The reaction 
was carried out at 0 °C for 24 hours. Solvents were 
removed under vacuum and reaction was repeated to 
improve the yield. The crude product was purified by silica 
flash column chromatography (95% DCM, 5% EtOH). 
Experimental Data Analysis. Purity of compounds was 
checked with Varian Unity 300 and Varian Unity 400 
NMR spectrometers. Liquid chromatography coupled with 
mass spectroscopy was employed for further analysis of 
compounds. Electro spray (ES+) was used as ionisation 
mode. A Micromass LCT mass spectrometer and a LC 
Waters 2795 instrument were used. 
Conclusion 
Various mono-substituted tryptophan analogues were 
synthesised using a combined acylation-resolution 
methodology. A wide range of substrates demonstrated the 
feasibility of the methodology. Using a variety of indole 
derivatives it was shown that this synthesis provides a 
facile route to protein chemistry precursors such as L- and 
D-Fmoc-protected tryptophan analogues. Mimics of the 
amino acid as it is as a residue in proteins were synthesised 
in good yield and optical purity. 
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Supporting Information 
N-Acetyl-5-fluoro-D,L-tryptophan 
1H NMR (400 MHz, MeOH – d4): δ 1.90 (s, 3H), 3.11 (dd, 
J = 7.6, 15.6, 1H), 3.26 (d, J = 6.0 , 1H), 4.68 (dd, J = 5.2, 
7.6, 1H), 6.84 (dt, J = 2.8, 8.4, 1H), 7.14 (s, 1H), 7.21 (dd, 
J = 2.0, 10.0, 1H), 7.26 (dd, 1H, J = 3.6, 8.4 Hz). 13C NMR 
(100 MHz, MeOH – d4): δ 22.38, 28.44, 54.71, 103.77, 
110.31, 110.57, 112.95, 113.05, 126.38, 134.56, 157.80, 
160.11, 173.18. MS (ES+) m/e 287.1 [m+Na]+. Mp  
N-Acetyl-5-chloro-D,L-tryptophan 
1H NMR (400 MHz, Acetone – d6): δ 1.90 (s, 3H), 3.17 
(dd, 1H, J = 7.0, 15.0 Hz ), 3.30 (dd, 1H, J = 5.5, 15.0 Hz), 
4.77 (dd, 1H, J = 5.5, 13.0 Hz), 7.06 (d, 1H, J = 7.5 Hz), 
7.24 (s, 1H), 7.27 (d, 1H, J = 7.5 Hz), 7.60 (s, 1H); 13C 
NMR (100 MHz, MeOH – d4): δ 22.40, 28.32, 54.75, 
108.27, 111.51, 112.19, 120.35, 124.44, 124.75, 130.56, 
136.02, 173.18, 175.11,; MS (ES+) m/e 303.2 [m+Na]+, 
305.2 [m+Na]+ 
N-Acetyl-5-bromo-D,L-tryptophan 
1H NMR (400 MHz, MeOH – d4): δ 1.91 (s, 3H), 3.12 (dd, 
1H, J = 6.4, 12 Hz), 3.30 (dd, 1H, J = 4.4, 11.6 Hz), 4.70 
(dd, 1H, J = 4.0, 6.0 Hz), 6.98 (dt, 1H, J = 1.6, 6.8 Hz), 
7.10 (s, 1H), 7.31 (d, 1H, J = 1.2 Hz), 7.49 (d, 1H, J = 2.8 
Hz); 13C NMR (100 MHz, MeOH – d4): δ 22.41, 28.28, 
54.81, 111.02, 112.99, 113.92, 121.94, 125.08, 125.93, 
130.76, 136.62, 173.18, 175.23; MS (ES+) m/e 347.1 
[m+Na]+, 349.1 [m+Na]+, 325.1 [m+H]+, 327.1 [m+H]+ 
N-Acetyl-5-iodo-D,L-tryptophan 
1H NMR (400 MHz, MeOH – d4): δ 1.92 (s, 3H), 3.10 (dd, 
1H, J = 8.0, 14.8 Hz), 3.31 (dd, 1H, J = 5.2, 14.8 Hz), 4.67 
(dd, 1H, J = 5.2, 8.0 Hz), 7.07 (s, 1H), 7.14 (d, 1H, J = 8.4 
Hz), 7.32 (dd, 1H, J = 1.6, 8.4 Hz), 7.88 (d, 1H, J = 1.6 
Hz); 13C NMR (100 MHz, MeOH – d4): δ 22.46, 28.23, 
54.83, 82.75, 110.69, 114.43, 125.58, 128.37, 130.67, 
131.61, 137.01, 173.18, 174.95; MS (ES+) m/e 395.1 
[m+Na]+ 
N-Acetyl-5-methoxy-D,L-tryptophan 
1H NMR (400 MHz, MeOH – d4): δ 1.91 (s, 3H), 3.12 (dd, 
1H, J = 7.6, 14.8 Hz), 3.30 (dd, 1H, J = 5.2, 14.4 Hz), 3.82 
(s, 3H), 4.70 (dd, 1H, J = 5.2, 7.2 Hz), 6.74 (dd, 1H, J = 2.0 
Hz, 8.8 Hz), 7.05 (s, 2H), 7.20 (d, 1H, J = 8.8 Hz); 13C 
NMR (100 MHz, MeOH – d4): δ 22.44, 30.68, 54.74, 
56.23, 101.09, 110.82, 112.72, 112.92, 125.06, 129.06, 
133.23, 155.09, 173.19, 175.28; MS (ES+) m/e 299.1 
[m+Na]+ 
N-Acetyl-5-nitro-D,L-tryptophan 
1H NMR (400 MHz, MeOH – d4): δ 1.92 (s, 3H), 3.22 (dd, 
1H, J = 7.6, 14.8 Hz), 3.39 (dd, 1H, J = 5.2, 14.8 Hz), 4.74 
(dd, 1H, J = 5.2, 7.6 Hz), 7.31 (s, 1H), 7.43 (d, 1H, J = 7.2 
Hz), 8.01 (dd, 1H, J = 2.0, 8.8 Hz), 8.56 (d, 1H, J = 2.4 
Hz); 13C NMR (100 MHz, MeOH – d4): δ 22.39, 28.14, 
54.70, 112.45, 114.26, 116.82, 116.82, 117.84, 128.25, 
141.01, 142.46, 173.21, 174.65; MS (ES+) m/e 314.1 
[m+Na]+ 
N-Acetyl-6-fluoro-D,L-tryptophan 
1H NMR (500 MHz, MeOH – d4): δ 1.90 (s, 3H), 3.12 (dd, 
1H, J = 8.0, 14.5 Hz), 4.69 (dd, 1H, J = 5.5, 10 Hz), 6.79 
(dt, 1H, J = 2.5 Hz, 10.0 Hz), 7.01 (dd, 1H, J = 2.0 Hz, 10.0 
Hz), 7.07 (s, 1H), 7.45 (dd, 1H, J = 5.5 Hz, 9.0 Hz); 13C 
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NMR (125 MHz, MeOH – d4): δ 22.37, 28.43, 54.71, 
108.09, 110.14, 111.40, 120.14, 124.79, 125.60, 137.87, 
160.23, 173.18, 175.12; MS (ES+) m/e 287.1 [m+Na]+, 
265.1 [m+H]+ 
N-Acetyl-6-chloro-D,L-tryptophan 
1H NMR (500 MHz, MeOH – d4): δ 1.89 (s, 3H), 3.12 (dd, 
1H, J = 8.0, 15 Hz), 4.70 (dd, 1H, J = 5.0, 7.5 Hz), 6.98 
(dd, 1H, J = 2.0, 8.5 Hz), 7.10 (s, 1H), 7.31 (d, 1H, J = 1.5 
Hz), 7.50 (d, 1H, J = 6.5 Hz); 13C NMR (125 MHz, MeOH 
– d4): δ 22.38, 28.33, 54.69, 111.50, 112.03, 120.28, 
120.34, 125.3, 127.59, 128.29, 138.33, 173.17, 175.07; MS 
(ES+) m/e 303.1 [m+Na]+, 305.1 [m+Na]+, 281.1 [m+H]+, 
283.1 [m+H]+ 
N-Acetyl-6-bromo-D,L-tryptophan 
1H NMR (400 MHz, MeOH – d4): δ 1.89 (s, 3H), 3.12 (dd, 
1H, J = 8.0, 14.4 Hz), 4.69 (dd, 1H, J = 4.2, 8.4 Hz), 7.09 
(s, 1H), 7.11 (dd, 1H, J = 2.0, 8.8 Hz), 7.45 (s, 1H), 7.47 
(m, 1H); 13C NMR (100 MHz, MeOH – d4): δ 22.38, 28.30, 
54.66, 111.80, 112.34, 120.97, 121,26, 125,83, 127.92, 
128.34, 138.55, 173.18, 175.10; MS (ES+) m/e 347.2 
[m+Na]+, 349.2 [m+Na]+ 
N-Acetyl-6-methyl-D,L-tryptophan 
1H NMR (500 MHz, MeOH – d4): δ 1.89 (s, 3H), 2.40 (s, 
3H), 3.11 (dd, 1H, J = 8.0, 14.5 Hz), 4.69 (dd, 1H, J = 5.0, 
8.0 Hz), 6.85 (d, 1H, J = 8.5 Hz), 6.99 (s, 1H), 7.11 (s, 1H), 
7.42 (d, 1H, J = 9.0 Hz), 7.63 (s, 1H); 13C NMR (125 MHz, 
MeOH – d4): δ 21.78, 22.39, 28.55, 54.80, 110.90, 112.12, 
118.93, 121.54, 123.61, 126.83, 132.02, 138.49, 173.18, 
175.28; MS (ES+) m/e 283.2 [m+Na]+, 261.2 [m+H]+  
N-Acetyl-6-methoxy-D,L-tryptophan 
1H NMR (500 MHz, MeOH – d4): δ 1.90 (s, 3H), 3.09 (dd, 
1H, J = 8.0, 14.5 Hz), 3.29 (dd, 1H, J = 6.0, 14.5 Hz), 3.78 
(s, 3H), 4.67 (dd, 1H, J = 5.0, 7.5 Hz), 6.67 (dd, 1H, J = 8.0 
Hz), 6.80 (d, 1H, J = 8.5 Hz), 7.36 (s, 1H), 7.63 (s, 1H); 13C 
NMR (125 MHz, MeOH – d4): δ 22.44, 30.68, 55.18, 
57.12, 94.50, 108.62, 110.01, 118.78, 121.64, 125.06, 
136.30, 155.21, 169.27, 173.63 ; MS (ES+) m/e 283.2 
[m+Na]+, 261.2 [m+H] 
N-Acetyl-6-nitro-D,L-tryptophan 
1H NMR (500 MHz, MeOH – d4): δ 1.90 (s, 3H), 3.09 (dd, 
1H, J = 8.0, 14.5 Hz), 3.29 (dd, 1H, J = 6.0, 14.5 Hz), 3.78 
(s, 3H), 4.67 (dd, 1H, J = 5.0, 7.5 Hz), 6.67 (dd, 1H, J = 8.0 
Hz), 6.80 (d, 1H, J = 8.5 Hz), 7.36 (s, 1H), 7.63 (s, 1H); 13C 
NMR (125 MHz, MeOH – d4): δ 22.44, 30.68, 55.18, 
57.12, 94.50, 108.62, 110.01, 118.78, 121.64, 125.06, 
136.30, 155.21, 169.27, 173.63 ; MS (ES+) m/e 283.2 
[m+Na]+, 261.2 [m+H] 
N-acetyl-5-fluoro-D-tryptophan 
1H NMR (400 MHz, MeOH – d4): δ 1.90 (s, 3H), 3.11 (dd, 
1H, J = 7.6, 14.8 Hz), 3.26 (d, 1H, J = 6.0 Hz), 4.68 (dd, 
1H, J = 5.2, 7.6 Hz), 6.84 (dt, 1H, J = 2.4, 9.2 Hz), 7.14 (s, 
1H), 7.21 (dd, 1H, J = 2.4, 10.4 Hz), 7.27 (dd, 1H, J = 4.8, 
8.8 Hz); 13C NMR (100 MHz, MeOH – d4): δ 22.38, 28.45, 
54.71, 103.77, 110.31, 111.34, 112.96, 126.38, 129.27, 
134.57, 157.81, 173.18, 175.13; MS (ES+) m/e 265.2 
[m+H]+ 
N-acetyl-5-chloro-D-tryptophan 
1H NMR (500 MHz, MeOH – d4): δ 1.91 (s, 3H), 3.11 (dd, 
1H, J = 10.0, 18.5 Hz), 3.29 (dd, 1H, J = 5.5, 18.5 Hz), 4.69 
(dd, 1H, J = 6.5, 10.5 Hz), 7.11 (dt, 1H, J = 3.0, 11.5 Hz), 
7.15 (s, 1H), 7.23 (dd, 1H, J = 3.0, 12.0 Hz), 7.68 (dd, 1H, J 
= 6.0, 11.0 Hz); 13C NMR (125 MHz, MeOH – d4): δ 
22.42, 28.23, 54.76, 110.91, 112.98, 113.90, 121.89, 
125.06, 125.91, 130.68, 136.53, 173.18, 175.27; MS (ES+) 
m/e 282.2 [m+H]+, 284.2 [m+H]+ 
N-acetyl-5-bromo-D-tryptophan 
1H NMR (400 MHz, MeOH – d4): δ 1.91 (s, 3H), 3.11 (dd, 
1H, J = 8.0, 14.4 Hz), 3.30 (dd, 1H, J = 5.2, 14.8 Hz), 4.69 
(dd, 1H, J = 5.2, 7.6 Hz), 7.12 (s, 1H), 7.16 (dd, 1H, J = 
2.0, 8.8 Hz), 7.24 (d, 1H, J = 8.8 Hz), 7.68 (d, 1H, J = 1.6 
Hz); 13C NMR (100 MHz, MeOH – d4): δ 22.41, 28.27, 
54.78, 111.00, 112.99, 113.93, 121.93, 125.09, 130.75, 
136.61, 173.19, 174.98; MS (ES+) m/e 325.2 [m+H]+, 
327.2 [m+H]+ 
N-acetyl-5-iodo-D-tryptophan 
1H NMR (400 MHz, MeOH – d4): δ 1.92 (s, 3H), 3.11 (dd, 
1H, J = 8.0, 14.8 Hz), 3.32 (dd, 1H, J = 5.2, 14.8 Hz), 4.69 
(dd, 1H, J = 5.2, 8.0 Hz), 7.07 (s, 1H), 7.14 (d, 1H, J = 8.4 
Hz), 7.32 (dd, 1H, J = 1.6, 8.4 Hz), 7.88 (d, 1H, J = 1.6 
Hz); 13C NMR (100 MHz, MeOH – d4): δ 22.48, 28.25, 
54.85, 82.73, 110.71, 114.40, 125.61, 128.39, 130.69, 
131.65, 137.05, 173.20, 174.91; MS (ES+) m/e 395.1 
[m+Na]+ 
N-acetyl-5-methyl-D-tryptophan 
1H NMR (400 MHz, MeOH – d4): δ 1.90 (s, 3H), 2.40 (s, 
3H), 3.10 (dd, 1H, J = 8.0, 14.8 Hz), 3.31 (dd, 1H, J = 4.8, 
14.8 Hz), 4.69 (dd, 1H, J =5.2, 8.0 Hz), 6.91 (dd, 1H, J = 
2.0, 8.0 Hz), 7.03 (s, 1H), 7.19 (d, 1H, J = 8.0 Hz), 7.33 (t, 
1H, J = 0.8 Hz); 13C NMR (100 MHz, MeOH – d4): δ 
21.69, 22.39, 28.49, 54.84, 110.53, 111.95, 118.86, 124.00, 
124.38, 128.80, 129.10, 136.40, 173.18, 175.31; MS (ES+) 
m/e 261.2 [m+H]+ 
N-acetyl-5-methoxy-D-tryptophan 
1H NMR (400 MHz, MeOH – d4): δ 1.91 (s, 3H), 3.12 (dd, 
1H, J = 8.0, 14.8 Hz), 3.30 (dd, 1H, J = 4.8, 14.8 Hz), 3.81 
(s, 3H), 4.69 (dd, 1H, J = 5.2, 8.0 Hz), 6.74 (dd, 1H, J = 
2.4, 8.8 Hz), 7.05 (s, 2H), 7.20 (d, 1H, J = 8.8 Hz); 13C 
NMR (100 MHz, MeOH – d4): δ 20.75, 22.44, 28.52, 
54.73, 56.24, 101.10, 110.81, 112.72, 125.07, 129.17, 
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133.22, 155.08, 173.19, 175.28; MS (ES+) m/e 276.1 
[m+H]+ 
N-acetyl-5-nitro-D-tryptophan 
1H NMR (400 MHz, MeOH – d4): δ 1.91 (s, 3H), 3.21 (dd, 
1H, J = 7.6, 14.8 Hz), 3.37 (dd, 1H, J = 5.6, 14.8 Hz), 4.76 
(dd, 1H, J = 5.6, 7.6 Hz), 7.32 (s, 1H), 7.43 (d, 1H, J = 7.2 
Hz), 8.01 (dd, 1H, J = 2.4, 8.4 Hz), 8.57 (d, 1H, J = 2.4 
Hz); 13C NMR (100 MHz, MeOH – d4): δ 22.41, 28.16, 
54.74, 112.52, 114.28, 116.85, 116.84, 117.86, 128.28, 
141.05, 142.44, 173.24, 174.63; MS (ES+) m/e 314.1 
[m+Na]+ 
N-acetyl-6-fluoro-D-tryptophan 
1H NMR (500 MHz, DMSO – d6): δ 1.78 (s, 3H), 2.96 (dd, 
1H, J = 9.5, 16 Hz), 3.11 (dd, 1H, J = 5.0, 15.0 Hz), 4.43 
(m, 1H), 6.83 (dd, 1H, J = 2.0 Hz, 9.5 Hz), 7.09 (dd, 1H, J 
= 2.5, 10.0 Hz), 7.12 (d, 1H, J = 2.5 Hz), 7.48 (dd, 1H, J = 
5.0, 7.0 Hz), 8.15 (d, 1H, J = 10.0 Hz), 10.90 (s, br, 1H); 
13C NMR (125 MHz, DMSO – d6): δ 20.39, 27.03, 52.89, 
97.19, 97.39, 106.71, 106.90, 119.19, 124.08, 135.90, 
157.86, 169.20, 173.47; MS (ES+) m/e 287.1 [m+Na]+ 
N-acetyl-6-chloro-D-tryptophan 
1H NMR (400 MHz, DMSO – d6): δ 1.78 (s, 3H), 2.96 (dd, 
1H, J = 8.8, 14.8 Hz), 3.12 (dd, 1H, J = 5.2, 14.8 Hz), 4.42 
(sex, 1H, J = 3.2, 6.8, 16.8 Hz), 6.98 (dd, 1H, J = 2.0, 8.4 
Hz), 7.17 (d, 1H, J = 2.4 Hz), 7.36 (d, 1H, J = 1.6 Hz), 7.51 
(d, 1H, J =8.4 Hz), 8.14 (d, 1H, J = 2.0 Hz), 10.98 (s, br, 
1H); 13C NMR (100 MHz, DMSO – d6): δ 20.78, 26.95, 
52.91, 110.39, 110.98, 118.69, 119.60, 124.74, 125.67, 
126.06, 136.42, 170.37, 173.45; MS (ES+) m/e 281.2 
[m+H]+, 283.2 [m+H]+ 
N-acetyl-6-bromo-D-tryptophan 
1H NMR (500 MHz, DMSO – d6): δ 1.78 (s, 3H), 2.96 (dd, 
1H, J = 9.0, 15 Hz), 3.11 (dd, 1H, J = 5.0, 14.0 Hz), 4.42 
(dd, 1H, J = 7.0, 11.0 Hz), 7.10 (dd, 1H, J = 2.0, 8.5 Hz), 
7.16 (d, 1H, J = 2.5 Hz), 7.47 (d, 1H, J = 9.0 Hz), 7.50 (d, 
1H, J = 1.5 Hz), 8.11 (d, 1H, J = 7.5 Hz), 10.65 (s, br, 1H); 
13C NMR (125 MHz, DMSO – d6): δ 20.76, 26.92, 52.89, 
110.40, 113.68, 113.90, 120.00, 121.21, 124.66, 126.29, 
136.92, 170.34, 173.40; MS (ES+) m/e 347.1 [m+Na]+, 
349.1 [m+Na]+ 
N-acetyl-6-methyl-D-tryptophan 
1H NMR (500 MHz, DMSO – d6): δ 1.78 (s, 3H), 2.36 (s, 
3H), 2.93 (dd, 1H, J = 8.5, 14.5 Hz), 3.10 (dd, 1H, J = 5.5, 
15.0 Hz), 4.42 (dd, 1H, J = 7.0, 9.5 Hz), 6.80 (dd, 1H, J = 
4.0, 8.0 Hz), 7.02 (d, 1H, J = 2.0 Hz), 7.10 (s, 1H), 7.38 (d, 
1H, J = 8.0 Hz), 8.11 (d, 1H, J = 9.5 Hz), 10.65 (s, br, 1H); 
13C NMR (100 MHz, DMSO – d6): δ 20.77, 22.41, 27.22, 
52.98, 109.80, 111.18, 117.88, 120.12, 122.77, 125.16, 
129.87, 136.53, 170.36, 173.59; MS (ES+) m/e 261.2 
[m+H]+ 
N-acetyl-6-methoxy-D-tryptophan 
1H NMR (500 MHz, DMSO – d6): δ 1.78 (s, 3H), 2.94 (dd, 
1H, J = 8.5, 14.5 Hz), 3.06 (dd, 1H, J = 5.5, 14.5 Hz), 3.73 
(s, 3H), 4.40 (dd, 1H, J = 7.0, 9.5 Hz), 6.63 (dd, 1H, J = 
3.0, 11.0 Hz), 6.81 (d, 1H, J = 3.0 Hz), 7.34 (d, 1H, J = 3.0, 
11.0 Hz), 8.11 (d, 1H, J = 9.5 Hz), 10.62 (s, br, 1H); 13C 
NMR (100 MHz, DMSO – d6): δ 22.43, 27.24, 55.15, 
59.79, 94.45, 108.60, 109.98, 118.77, 121.60, 122.09, 
136.79, 155.48, 170.39, 173.62; MS (ES+) m/e 276.2 
[m+H]+ 
5-Fluoro-L-tryptophan 
1H NMR (400 MHz, MeOH – d4): δ 3.14 (dd, 1H, J = 8.8 
Hz, 15.2 Hz), 3.82 (dd, 1H, J = 4.0 Hz, 9.2 Hz), 6.88 (dt, 
1H, J = 1.6, 9.2 Hz), 7.24 (s, 1H), 7.31 (dd, 1H, J = 4.8, 8.4 
Hz), 7.40 (dd, 1H, J = 2.4 Hz, 10.0 Hz); 13C NMR (100 
MHz, MeOH – d4): δ 28.34, 56.54, 104.05, 109.73, 110.71, 
113.24, 127.18, 128.83, 134.91, 160.26, 174.33; MS (ES+) 
m/e 223.1 [m+H]+ 
(Lit.x 1H NMR (300 MHz, MeOD) δ 3.14 (βH), 3.84 (αH), 
6.87 (H-6), 7.21 (H-2), 7.27 (H-7), 7.33 (H-4); 13C NMRxiii 
(75.5 MHz, D2O) δ 26.8, 57.8, 103.5, 108.0, 110.8, 113.1, 
127.0, 127.3, 131.2, 159.4, 175.0; MSxiii (EI) m/e 222 [M]+) 
5-Chloro-L-tryptophan 
1H NMR (500 MHz, MeOH – d4): δ 3.14 (dd, 1H, J = 9.0, 
15.0 Hz), 3.43 (dd, 1H, J = 4.0, 15.0 Hz), 3.83 (dd, 1H, J = 
4.5, 9.0 Hz), 7.07 (d, 1H, J = 2.0, 9.0 Hz), 7.25 (s, 1H), 
7.32 (d, 1H, J = 9.0 Hz), 7.73 (d, 1H, J = 2.0 Hz); 13C NMR 
(100 MHz, MeOH – d4): δ 28.22, 57.9, 109.47, 113.64, 
118.95, 122.87, 126.00, 126.94, 129.68, 136.71, 174.36; 
MS (ES+) m/e 239.1 [m+H]+, 241.1 [m+H]+ 
(Lit.x 1H NMR (300 MHz, MeOD) δ 2.90 (αH), 3.26 (βH), 
3.54 (βH), 7.05 (H-6), 7.20 (H-2), 7.31 (H-7), 7.73 (H-4); 
MSxiv (EI) m/e 238 [M]+, 240 [M]+) 
5-Bromo-L-tryptophan 
1H NMR (400 MHz, MeOH – d4): δ 3.08 (dd, 1H, J = 8.8, 
15.4 Hz), 3.43 (dd, 1H, J = 4.0 Hz, 15.4 Hz), 3.80 (dd, 1H, 
J = 4.4 Hz, 9.2 Hz), 7.19 (d, 1H, J = 2.0 Hz), 7.21 (m, 1H), 
7.28 (d, 1H, J = 8.8 Hz), 7.90 (d, 1H, J = 1.6 Hz); MS 
(ES+) m/e 283.0 [m+H]+, 285.1 [m+H]+, 305.1 [m+Na]+, 
307.1 [m+Na]+ 
(Lit.x 1H NMR (300 MHz, D2O) δ 2.90 (αH), 3.26 (βH), 
3.54 (βH), 7.05 (H-6), 7.20 (H-2), 7.31 (H-7), 7.73 (H-4); 
MSxiv (EI) m/e 238 [M]+, 240 [M]+) 
5-Iodo-L-tryptophan 
1H NMR (500 MHz, MeOH – d4): δ 3.11 (dd, 1H, J = 9.0, 
15.0 Hz), 3.43 (dd, 1H, J = 4.0 Hz, 15.0 Hz), 3.83 (dd, 1H, 
J = 4.0 Hz, 9.0 Hz), 7.18 (d, 1H, J = 2.0 Hz), 7.19 (s, 1H), 
7.36 (dd, 1H, J = 2.0, 9.0 Hz), 8.09 (d, 1H, J = 1.5 Hz); 13C 
NMR (100 MHz, MeOH – d4): δ 28.20, 56.56, 83.13. 
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109.10, 114.59, 126.35, 128.43, 130.00, 131.06, 137.36, 
174.40; MS (ES+) m/e 331.1 [m+H]+ 
(Lit.xi 1H NMR (500 MHz, DMSO) δ 2.96 (αH, dd, J = 8.3, 
15.0 Hz), 3.22 (βH, dd, J = 4.2, 15.0 Hz), 3.39 (βH, dd, J = 
4.2, 8.3 Hz), 7.20 (H-6, s), 7.21 (H-2, d, J = 8.4 Hz), 7.31 
(H-7, dd, J = 1.6, 8.4 Hz), 7.92 (H-4, d, J = 1.6 Hz); MSxi 
(CI) m/e 331.0 [m+H]+) 
5-Methyl-L-tryptophan 
1H NMR (300 MHz, MeOH – d4): δ 2.42 (s, 3H), 3.09 (dd, 
1H, J = 9.0, 15.2 Hz), 3.49 (dd, 1H, J = 4.5, 15.2 Hz), 3.84 
(dd, 1H, J = 4.5, 9.3 Hz), 6.94 (d, 1H, J = 4.8 Hz), 7.13 (s, 
1H), 7.23 (d, 1H, J = 4.8 Hz), 7.50 (s, 1Hz); 13C NMR (125 
MHz, MeOH – d4): δ 21.64, 28.54, 56.74, 109.08, 112.15, 
118.95, 124.39, 125.18, 128.68, 129.26, 136.77, 174.45; 
MS (ES+): 219.1 [m+H]+ 
(Lit. 1H NMRxii (300 MHz, MeOD) δ 2.43, 2.85, 3.32, 3.57, 
6.94, 7.09, 7.25, 7.51; MSxiii (EI) m/e 218 [M+]) 
5-Methoxy-L-tryptophan 
1H NMR (400 MHz, MeOH – d4): δ 3.10 (dd, 1H, J = 5.6, 
15.2 Hz), 3.47 (dd, 1H, J = 3.6, 15.2 Hz), 3.83 (s, 3H), 6.76 
(dd, 1H, J = 2.4 Hz, 8.8 Hz), 7.15 (s, 1H), 7.23 (d, 1H, J = 
0.8 Hz), 7.24 (d, 1H, J = 4.8 Hz); 13C NMR (100 MHz, 
MeOH – d4): δ 28.62, 56.25, 56.51, 101.09, 109.34, 113.13, 
113.24, 125.85, 128.73, 133.53, 155.36, 174.63; MS (ES+): 
m/e 234.1 [m+H]+ 
Lit.xiv 1H NMR (D2O): δ 3.0 - 3.7 (2H, m, CH2), 3.8 – 4.2 
(2H, m, CH), 3.85 (3H, s, OCH3), 6.80 (1H, dd, J = 2, 9 
Hz, C(6)-H), 7.20 (1H, s, C(2)-H), 7.20 (1H, d, J = 2 Hz, 
(C(4)-H), 7.30 (1H, d, J = 9 Hz, C(7)-H); MS m/e (EI) 234 
[m+] 
 5-Nitro-L-tryptophan 
1H NMR (500 MHz, MeOH – d4): δ 3.27 (dd, 1H, J = 8.5, 
15.5 Hz), 3.50 (dd, 1H, J = 4.0, 15.5 Hz), 3.88 (dd, 3H, J = 
4.5, 8.5 Hz), 7.42 (s, 1H), 7.45 (s, 1H), 8.04 (d, 1H, J = 9.0 
Hz), 8.78 (d, 1H, J = 2.0 Hz); 13C NMR (125 MHz, MeOH 
– d4): δ 27.91, 56.52, 110.56, 112.56, 117.09, 118.14, 
126.70, 128.07, 129.02, 142.71, 174.08; MS (ES+): m/e 
234.1 [m+H]+ 
Lit. 1H NMRxiv (D2O): δ 3.12 (1H, dd, J = 7.5, 15.1 Hz, 
CH), 3.29 (1H, dd, J = 4.2, 15.1 Hz, CH2), 3.44 (1H, dd, J 
= 4.5, 7.4 Hz, CH2), 7.44 (1H, s, C(2)-H), 7.51 (1H, d, J = 
9.0 Hz, C(6)-H), 7.97 (1H, dd, J = 2.2, 9.0 Hz, (C(7)-H), 
8.63 (1H, d, J = 2.2 Hz, C(4)-H) 
6-Fluoro-L-tryptophan 
1H NMR (400 MHz, MeOH – d4): δ 3.11 (dd, 1H, J = 9.2, 
15.6 Hz), 3.45 (dd, 1H, J = 4.4, 15.6 Hz), 3.80 (dd, 1H, J = 
4.0 Hz, 9.2 Hz), 6.82 (dt, 1H, J = 2.0, 6.1 Hz), 7.04 (dd, 
1H, J = 2.4, 10.0 Hz), 7.17 (s, 1H), 7.65 (dd, 1H, J = 5.2, 
8.8 Hz); 13C NMR (100 MHz, MeOH – d4): δ 28.69, 56.67, 
98.14, 98.39, 108.36, 108.61, 120.35, 125.26, 125.62, 
135.26, 174.91; MS (ES+) m/e 235.1 [m+H]+ 
Lit.x 1H NMR (300 MHz, MeOH – d4): δ 3.13, 3.47, 3.84, 
6.82, 7.05, 7.17, 7.64; 13C NMR (60 MHz, MeOH – d4): δ 
98.3, 108.5, 109.8, 120.4, 125.2, 125.6, 138.3, 161.4 
6-Chloro-L-tryptophan 
1H NMR (400 MHz, MeOH – d4): δ 3.15 (dd, 1H, J = 9.2, 
15.6 Hz), 3.46 (dd, 1H, J = 4.0, 15.6 Hz), 3.82 (dd, 1H, J = 
4.0 Hz, 9.2 Hz), 7.00 (dd, 1H, J = 2.0 Hz, 8.8 Hz), 7.21 (s, 
1H), 7.35 (d, 1H, J = 1.6 Hz), 7.65 (d, 1H, J = 8.4 Hz); 13C 
NMR (100 MHz, MeOH – d4): δ 28.26, 56.58, 110.02, 
115.26, 116.18, 120.96, 123.21, 126.09, 127.53. 139.19, 
174.28; MS (ES+) m/e 222 [m-NH3]+, 239 [m+H]+ 
Lit.: 1H NMRxii (300 MHz, MeOH – d4): δ 2.93, 3.27, 3.55, 
6.99, 7.18, 7.35, 7.67; 13C NMRxii (60 MHz, MeOH – d4): δ 
32.5, 57.9, 111.9, 112.9, 120.9, 125.5, 127.8, 128.2, 138.5, 
182.2; MSxv m/e (EI) 238.0 [m+] 
6-Bromo-L-tryptophan 
1H NMR (400 MHz, MeOH – d4): δ 3.15 (dd, 1H, J = 7.2, 
12.4 Hz), 3.46 (dd, 1H, J = 3.2, 12.4 Hz), 3.82 (dd, 1H, J = 
3.6, 7.2 Hz), 7.14 (dd, 1H, J = 1.2, 6.8 Hz), 7.19 (s, 1H), 
7.52 (d, 1H, J = 1.2 Hz), 7.61 (d, 1H, J = 6.8 Hz); 13C NMR 
(100 MHz, MeOH – d4): δ 28.21, 56.49, 109.89, 112.22, 
120.54, 120.60, 126.31, 127.23, 128.59, 138.68, 174.57; 
MS (ES+) m/e 283.2 [m+H]+, 285.2 [m+H]+ 
6-Methyl-L-tryptophan 
1H NMR (400 MHz, MeOH – d4): δ 3.08 (dd, 1H, J = 8.0, 
12.2 Hz), 3.34 (s, 3H), 3.48 (dd, 1H, J = 2.8, 12.2 Hz), 3.83 
(dd, 1H, J = 3.2, 7.6 Hz), 6.88 (d, 1H, J = 6.4 Hz), 7.10 (s, 
1H), 7.15 (s, 1H), 7.57 (d, 1H, J = 6.4 Hz); 13C NMR (125 
MHz, MeOH – d4): δ 21.79, 28.57, 56.68, 109.41, 112.29, 
119.07, 121.87, 124.48, 126.39, 132.47, 138.87, 174.48; 
MS (ES+) m/e 219.1 [m+H]+, 241.1 [m+Na]+ 
Lit.:xii 1H NMR (300 MHz, MeOH – d4): δ 2.43, 2.88, 3.31, 
3.56, 6.86, 7.06, 7.14, 7.58; 13C NMR (60 MHz, MeOH – 
d4): δ 112.0, 112.3, 119.4, 121.4, 124.8, 127.0, 131.7 
6-Methoxy-L-tryptophan 
1H NMR (400 MHz, MeOH – d4): δ 3.11 (dd, 1H, J = 6.0, 
15.2 Hz), 3.44 (dd, 1H, J = 4.0, 15.2 Hz), 3.79 (s, 3H), 6.76 
(dd, 1H, J = 2.4 Hz, 8.4 Hz), 6.86 (s, 1H), 7.24 (d, 1H, J = 
0.8 Hz), 7.26 (d, 1H, J = 4.8 Hz); 13C NMR (100 MHz, 
MeOH – d4): δ 28.85, 55.21, 58.24, 101.15, 109.40, 113.18, 
113.27, 125.83, 128.76, 133.52, 155.46, 174.65; MS (ES+) 
m/e 235.2 [m+H]+, 259.2 [m+Na]+ 
Fmoc-5-F-L-tryptophan 
1H NMR (300 MHz, MeOH – d4): δ 3.12 (dd, 1H, J = 8.7, 
14.7 Hz), 4.15 (dd, 1H, J = 6.9, 14.1 Hz), 4.22-4.33 (m, 
2H), 4.47 (dd, 1H, J = 4.8, 8.4 Hz), 6.85 (dt, 1H, J = 2.4, 
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9.0 Hz), 7.14 (s, 1H), 7.21-7.30 (m, 4H), 7.36 (t, 2H, J = 
7.5), 7.57 (d, 2H, J = 7.5), 7.76 (d, 2H, J = 7.5); MS (ES+) 
m/e 445.4 [m+Na]+ 
Fmoc-5-MeO-L-tryptophan 
1H NMR (400 MHz, MeOH – d4): δ 3.12 (m, 1H), 4.15 (m, 
2H), 4.68 (m, 1H), 6.72 (dd, 1H, J = 2.2 Hz, 0.6 Hz), 7.05 
(dd, 1H, J = 3.8 Hz, 0.5 Hz), 7.20 (m, 1.5H), 7.34 (m, 1H), 
7.55 (d, 1H, J = 1.6 Hz), 7.57 (d, 1H, J = 1.9Hz); 13C NMR 
(100MHz, MeOH – d4): δ 28.71, 56.22, 56.36, 68.04, 
101.18, 112.66, 112.94, 120.87, 125.21, 126.27, 126.36, 
128.17, 128.74, 142.52, 145.25; MS (ES+) m/e 465.2 
[m+Na]+ 
N-acetyl-5-methoxy-L-tryptophan 
1H NMR (400 MHz, MeOH – d4): δ 1.91 (s, 3H), 3.12 (dd, 
1H, J = 8.0, 14.8 Hz), 3.30 (dd, 1H, J = 4.8, 14.8 Hz), 3.81 
(s, 3H), 4.69 (dd, 1H, J = 5.2, 8.0 Hz), 6.74 (dd, 1H, J = 
2.4, 8.8 Hz), 7.05 (s, 2H), 7.20 (d, 1H, J = 8.8 Hz); 13C 
NMR (100 MHz, MeOH – d4): δ 20.75, 22.44, 28.52, 
54.73, 56.24, 101.10, 110.81, 112.72, 125.07, 129.17, 
133.22, 155.08, 173.19, 175.28; MS (ES+) m/e 276.2 
[m+H]+ 
Lit.:xiv 1H NMR (400 MHz, CDCl3): δ  
N-acetyl-5-nitro-L-tryptophan 
1H NMR (400 MHz, MeOH – d4): δ 1.92 (s, 3H), 3.15 (dd, 
1H, J = 8.4, 14.8 Hz), 3.31 (dd, 1H, J = 5.2, 14.8 Hz). 4.65 
(dd, 1H, J = 5.6, 8.4 Hz), 7.19 (dd, 1H, J = 2.4, 8.8 Hz), 
7.45 (d, 1H, J = 2.4 Hz), 8.08 (s, 1H), 8.13 (d, 1H, J = 8.8 
Hz); 13C NMR (100 MHz, CDCl3): δ 23.74, 29.97, 55.18, 
109.79, 112.15, 114.60, 122.52, 125.78, 129.12, 132.72, 
144.16, 171.67, 174.44; MS (ES+) m/e 314.1 [m+Na]+ 
N-Ac-L-W-OMe 
1H NMR (500 MHz, MeOH – d4): δ 1.91 (s, 3H), 3.14 (dd, 
1H, J = 8.0, 14.5 Hz), 3.27 (dd, 1H, J = 6.0, 14.5 Hz), 3.64 
(s, 3H), 4.71 (dd, 1H, J = 6.0, 7.5 Hz), 7.00 (dt, 1H, J = 1.0, 
7.5 Hz), 7.06 (s, 1H), 7.08 (dt, 1H, J = 1.0, 7.5 Hz), 7.31 (d, 
1H, J = 8.0 Hz), 7.50 (d, 1H, J = 1.0, 8.0 Hz); 13C NMR 
(125 MHz, MeOH – d4): δ 22.31, 28.50, 52.64, 55.02, 
110.73, 112.30, 119.09, 119.80, 122.43, 124.32, 128.72, 
138.04, 173.21, 174.05; mp.: 144 °C 
Lit.: mpxvi.: 155-156 °C 
N-Ac-5-F-L-W-OMe 
1H NMR (200 MHz, CDCl3): δ 2.05 (s, 3H), 3.23 (dd, 1H, J 
= 7.6, 14.6 Hz), 3.37 (dd, 1H, J = 5.8, 14.6 Hz), 3.79 (s, 
3H), 4.83 (dd, 1H, J = 6.0, 7.4 Hz), 6.97 (dt, 2H, J = 2.4, 
9.0 Hz), 7.27 (d, 1H, J = 2.4 Hz), 7.32 (d, 1H, J = 2.4 Hz), 
7.39 (d, 1H, J = 4.6 Hz), 7.43 (d, 1H, J = 2.4 Hz); MS 
(ES+) m/e 279.1 [m+H]+, 301.1 [m+Na]+ 
N-Ac-5-MeO-L-W-OMe 
1H NMR (400 MHz, CDCl3): δ 1.96 (3H, s), 3.22-3.32 (2H, 
m), 3.69 (3H, s), 3.83(3H, s), 4.93 (1H, dquart, J = 2.4, 6.8 
Hz), 6.00 (1H, d, J = 8.8 Hz), 6.84 (1H, dd, J = 2.4, 8.8 
Hz), 6.93 (1H, d, J = 2.4 Hz), 6.96 (1H, d, J = 2.4 Hz), 
7.221 (1H, d, J = 8.8 Hz), 7.99 (1H, s, br); 13C NMR (100 
MHz, CDCl3): δ 25.30, 29.61, 54.40, 55.00, 102.13, 
111.85, 114.01, 114.68, 125.33, 130.14, 133.18, 156.29, 
171.75, 174.42; MS (ES+) m/e 291.1 [m+H]+, 313.1 
[m+Na]+ 
N-Ac-5-NO2-L-W-OMe 
1H NMR (400 MHz, CDCl3): δ 1.97 (3H, s), 3.22-3.32 (2H, 
m), 3.68 (3H, s), 4.96 (1H, dq, J = 2.4, 6.8 Hz), 7.18 (1H, d, 
J = 8.8 Hz), 7.38 (1H, dd, J = 2.4, 8.8 Hz), 7.44 (1H, d, J = 
2.4 Hz), 8.05 (1H, s), 8.11 (1H, d, J = 8.8 Hz), 8.33 (1H, s, 
br); 13C NMR (100 MHz, CDCl3): δ 23.98, 30.01, 52.43, 
54.81, 109.74, 112.11, 114.57, 122.43, 125.87, 129.15, 
132.68, 144.13, 171.64, 174.43; MS (ES+) m/e 306.1 
[m+H]+, 328.1 [m+Na]+ 
N-Ac-L-W-NEt 
1H NMR (200 MHz, CDCl3): δ 0.85 (t, 3H, 7.4 Hz), 1.96 
(s, 3H), 3.02 – 3.13 (m, 3H), 3.27 (dd, 1H, J = 5.2, 14.2 
Hz), 4.65 (quartett, 1H, J = 5.2 Hz), 5.55 (s, br, 1H), 6.46 
(d, 1H, J = 5.2 Hz), 7.02 (d, 1H, J = 2.4 Hz), 7.10 (dt, 1H, J 
= 1.2, 7.0 Hz), 7.18 (dt, 1H, J = 1.2, 7.0 Hz), 7.34 (d, 1H, J 
= 7.2 Hz), 7.68 (d, 1H, J = 7.2 Hz), 8.26 (s, br, 1H); 13C 
NMR (125 MHz, MeOH – d4): δ 14.81, 22.56, 30.12, 
34.75, 53.71, 110.73, 111.38, 119.09, 119.82, 122.45, 
124.30, 128.75, 138.07, 173.25, 174.07; MS (ES+) m/e 
274.2 [m+Na]+ 
Lit.:xvii MS (EI) m/e 273.2 [m]+ 
N-Ac-5-F-L-W-NEt 
1H NMR (500 MHz, CDCl3): δ 0.87 (3H, t, J = 7.2 Hz), 
2.00 (3H, s), 3.01 (1H, dd. J = 9.2, 14.4 Hz), 3.04-3.17 (2H, 
m), 3.28 (1H, dd, J = 4.8, 14.4 Hz), 3.87 (3H, s), 4.60-4.65 
(1H, m), 5.39 (1H, s, br), 6.39 (1H, d, J = 7.2 Hz), 6.85 
(1H, dd, J = 2.4, 8.8 Hz), 7.01 (1H, d, J = 2.4 Hz), 7.22 
(1H, d, J = 2.4 Hz), 7.24 (1H, d, J = 8.8 Hz), 8.00 (1H, s, 
br); 13C NMR (100 MHz, CDCl3): δ 16.43, 25.36, 30.96, 
36.34, 54.34, 55.81, 102.28, 112.88, 114.01, 115.01, 
125.58, 130.14, 133.17, 156.35, 172.87; MS (ES+) m/e 
326.1 [m+Na]+ 
N-Ac-5-MeO-L-W-NEt 
1H NMR (400 MHz, CDCl3): δ 0.87 (3H, t, J = 7.2 Hz), 
2.00 (3H, s), 3.01 (1H, dd. J = 9.2, 14.4 Hz), 3.04-3.17 (2H, 
m), 3.28 (1H, dd, J = 4.8, 14.4 Hz), 3.87 (3H, s), 4.60-4.65 
(1H, m), 5.39 (1H, s, br), 6.39 (1H, d, J = 7.2 Hz), 6.85 
(1H, dd, J = 2.4, 8.8 Hz), 7.01 (1H, d, J = 2.4 Hz), 7.22 
(1H, d, J = 2.4 Hz), 7.24 (1H, d, J = 8.8 Hz), 8.00 (1H, s, 
br); 13C NMR (100 MHz, CDCl3): δ 16.43, 25.36, 30.96, 
36.34, 54.34, 55.81, 102.28, 112.88, 114.01, 115.01, 
125.58, 130.14, 133.17, 156.35, 172.87; MS (ES+) m/e 
326.1 [m+Na]+ 
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